Based on pre-clinical evidence of high expression of CD38 in T cells, daratumumab, a human moAb against CD38 approved in multiple myeloma, has shown a significant anti-leukemic effect in small case series of R/R T cell ALL and Ph-positive ALL [163, 164] and is being evaluated in a phase 2 clinical trial (NCT03384654). This evidence concerns the gene CD38 and plasma cell myeloma.